Helping our patient communities and advancing knowledge in our therapy areas is part of our corporate responsibility.
It is our mission to discover, develop, and deliver innovative therapies that improve patients' quality of life.
We work with government authorities to ensure patients have access to care while also funding medical research.
We also aim to make sure that nothing holds you back from getting the therapies you need.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise.
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health.
Every day at CSL Behring, we work as if someone’s life depends on it, because it does.
CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions.
Help us deliver on our promise to save lives and protect the health of people.
Make your well-being a priority. It's important and so are you.
Ready to get more exercise? Stacy Ahearn says “my immune system might be compromised but my passion for fitness is not.”
Learning she had the rare genetic disease Alpha 1 led Julie MacNeil to find her birth family.
Ironman finisher Stacy Ahearn on getting back in shape after a rare disease diagnosis.
Tell your healthcare team about physical limitations, says CIDP patient Elizabeth Thirtyacre.
Women who have the bleeding disorder often go undiagnosed, Duke doctor says.
Survey: Almost a third of women say they must “prove” symptoms to doctors
Find out why science education is essential and test what you know.
Video: Moms living with rare diseases offer Mother's Day wishes.
First episode marks World Hemophilia Day, features Duke University physician.
Meet some of the women who help create CSL’s leading-edge advances in science.
HAE patient Cheryl Blackwell-Johnson finds strength in her family’s unique bond.
Women with a family history of hemophilia could see symptoms like abnormal bleeding.
Popular search terms:
Americas
Asia Pacific
Europe
